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Purpose To provide resource-stratified, evidence-based recommendations on the secondary prevention of
cervical cancer globally.
MethodsASCOconvenedamultidisciplinary,multinationalpanelofoncology,primarycare,epidemiology,health
economic, cancer control, public health, and patient advocacy experts to produce recommendations reflecting
four resource-tiered settings. A review of existing guidelines, a formal consensus-based process, and amodified
ADAPTE process to adapt existing guidelines were conducted. Other experts participated in formal consensus.
Results Seven existing guidelines were identified and reviewed, and adapted recommendations form the
evidence base. Four systematic reviews plus cost-effectiveness analyses provided indirect evidence to
inform consensus, which resulted in ‡ 75% agreement.
Recommendations Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual
inspectionwithaceticacidmaybeused inbasicsettings.Recommendedage rangesand frequenciesbysetting
are as follows: maximal: ages 25 to 65, every 5 years; enhanced: ages 30 to 65, if two consecutive negative
tests at 5-year intervals, then every 10 years; limited: ages 30 to 49, every 10 years; and basic: ages 30 to 49,
one to three timesper lifetime.Forbasicsettings,visualassessment is recommendedas triage; inothersettings,
genotypingand/or cytologyare recommended. For basic settings, treatment is recommended if abnormal triage
resultsarepresent; inothersettings,colposcopy isrecommended forabnormal triageresults.Forbasicsettings,
treatment options are cryotherapy or loop electrosurgical excision procedure; for other settings, loop elec-
trosurgical excision procedure (or ablation) is recommended. Twelve-month post-treatment follow-up is
recommended in all settings.WomenwhoareHIV positive should be screenedwithHPV testing after diagnosis
andscreenedtwiceasmany timesper lifetimeas thegeneralpopulation.Screening is recommendedat6weeks
postpartum inbasic settings; inother settings, screening is recommendedat 6months. Inbasic settingswithout
mass screening, infrastructure for HPV testing, diagnosis, and treatment should be developed.
Additional information can be found at www.asco.org/rs-cervical-cancer-secondary-prev-guideline and www.
asco.org/guidelineswiki.
It is the viewof of ASCO that health care providers andhealth care systemdecisionmakers should beguidedby
the recommendations for the highest stratum of resources available. The guideline is intended to complement,
but not replace, local guidelines.
INTRODUCTION
The purpose of this guideline is to provide expert
guidance on secondary prevention with screen-
ing for cervical cancer to clinicians, public health
authorities, policymakers, and laypersons in all
resource settings. The target population is women
in the general population at risk for developing
cervical cancer (specific target ages depend on
the resource level).
There are large disparities regionally and globally
in incidence of and mortality resulting from cervi-
cal cancer, in part because of disparities in the
provision of mass screening and primary preven-
tion. Different regions of the world, both among
and within countries, differ with respect to access
to prevention and treatment.
Approximately 85% of incident cervical cancers
occur in less developed regions (also knownas low-
and middle-income countries [LMICs]) around
the world, representing 12% of women’s can-
cers in those regions. Eighty-seven percent of
deaths resulting from cervical cancer occur in
these less-developed regions.1 Some of the re-
gions in the world with the highest mortality
rates include the WHO Southeast Asia and
Western Pacific regions, followed by India and
Africa.1 As a result of these disparities, the ASCO
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THE BOTTOM LINE
Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline
Guideline Question
What are the optimal method(s) for cervical cancer screening and the management of women with
abnormal screening results for each resource level (ie, basic, limited, enhanced, maximal)?
Target Population
Women who are asymptomatic for cervical cancer precursors or invasive cervical cancer
Target Audience
Public health authorities, cancer control professionals, policymakers, obstetricians/gynecologists,
primary care providers, lay public
Methods
A multinational, multidisciplinary Expert Panel was convened to develop clinical practice guideline
recommendations on the basis of a systematic review of existing guidelines and/or an expert consensus
process.
Authors’ note: It is the view of ASCO that health care providers and health care system decision makers
should be guided by the recommendations for the highest stratumof resources available. The guidelines
are intended to complement, but not replace, local guidelines.
Key Recommendations
Primary Screening
·Human papillomavirus (HPV) DNA testing is recommended in all resource settings.·Visual inspection with acetic acid may be used in basic settings.·The recommended age ranges and frequencies in each setting are as follows:
◦Maximal: 25-65 years, every 5 years
◦Enhanced: 30-65 years, if two consecutive negative tests at 5-years intervals, then every
10 years
◦Limited: 30-49 years, every 10 years
◦Basic: 30-49 years, one to three times per lifetime
Exiting Screening
·Maximal and enhanced: > 65 years with consistently negative results during past > 15 years·Limited and basic: < 49 years, resource-dependent; see specific recommendations
Triage
·In basic settings, visual assessment for treatment may be used after positive HPV DNA testing
results.
◦If visual inspection with acetic acid was used as primary screening with abnormal results,
women should receive treatment.
·For other settings, HPV genotyping and/or cytology may be used.
After Triage
·Women with negative triage results should receive follow-up in 12 months.·In basic settings, women should be treated if there are abnormal or positive triage results.
(continued on following page)
2 jgo.ascopubs.org JGO – Journal of Global Oncology
Downloaded from ascopubs.org by Queen Mary and Westfield College on September 6, 2017 from 138.037.213.175
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
chose cervical cancer as a priority topic for
guideline development.
The primary goal of cervical cancer screening should
be—and the emphasis of these guidelines is—the
accurate detection and timely treatment of intra-
epithelial precursor lesions of the cervix at a pop-
ulation level for the purpose of cervical cancer
prevention, rather than cancer control as for many
other cancers. This is because these precursor
lesions are readily found and diagnosable and are
easily and effectively treated through outpatient ser-
vices with minimal adverse events or sequelae.
Earlier detection of cervical cancer at a lesser stage
is also a benefit of screening, resulting in reduced
morbidityandmortality.However,many low-resource
settings have little capacity in terms of surgery and
radiotherapy to treat women with invasive cervical
cancer.2 Therefore, the ASCO Expert Panel that de-
veloped this guideline (Appendix Table A1) empha-
sizes the timely detection and treatment of cervical
precancerous lesions before they become invasive.
To achieve this, a high screening coverage and an
organized screening program are necessary.
Human papillomavirus (HPV) causes virtually all
cervical cancer and its immediate precursors ev-
erywhere in the world. High-quality screening pro-
grams can lower the incidence of cervical cancer
by up to 80%.3 In the past three decades, mass
THE BOTTOM LINE (CONTINUED)
·In limited settings, womenwith abnormal results from triage should receive colposcopy, if available,
or visual assessment for treatment, if colposcopy is not available.
·In maximal and enhanced settings, women with abnormal or positive results from triage should
receive colposcopy.
Treatment of Women With Precursor Lesions
·Inbasic settings, treatment options arecryotherapyor loopelectrosurgical excisionprocedure (LEEP).·In other settings, LEEP (if high level of quality assurance) or ablation (if medical contraindication to
LEEP) is recommended.
·Twelve-month post-treatment follow-up is recommended for all settings.
Special Populations
·Womenwho areHIVpositive or immunosuppressed for other reasons should be screenedwithHPV
as soon as diagnosed and screened twice as many times in a lifetime as the general population.
·Themanagement of abnormal screening results for womenwith HIV and positive results of triage is
the same as in the general population
·Women should be offered primary screening 6 weeks postpartum in basic settings and 6 months
postpartum in other settings.
·Screeningmaybediscontinued inwomenwhohave receiveda total hysterectomy forbenigncauses
withnohistoryof cervicaldysplasiaorHPV.Womenwhohave receivedasubtotal hysterectomy (with
an intact cervix) should continue receiving routine screening.
Qualifying Statement
In basic settingswithout currentmass screening, infrastructure forHPV testing, diagnosis, and treatment
should be developed.
Additional Resources
More information, including a Data Supplement, a Methodology Supplement with information about
evidencequality and strength of recommendations, slide sets, and clinical tools and resources, is available
at www.asco.org/rs-cervical-cancer-secondary-prev-guideline and www.asco.org/guidelineswiki. Patient
information is available at www.cancer.net.
ASCO believes that cancer and cancer prevention clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
3 jgo.ascopubs.org JGO – Journal of Global Oncology
Downloaded from ascopubs.org by Queen Mary and Westfield College on September 6, 2017 from 138.037.213.175
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
screening in high-resource settings has achieved
these reductions in cervical cancer incidence.4 A
cervical cancer prevention program will affect the
incidenceandmortality rates only ifwomenwithpos-
itive screening results complete proper evaluation
and treatment to prevent the progression to invasive
cancer. Therefore, one of the critical evaluation indi-
cators for any population-based program is the rate
of completion of management and treatment in
womenwhorequire it,whichshould ideallybe100%.
In 2013 and 2014, WHO published guidelines on
the screening and treatment of precursor lesions
for women in all settings; this guideline reinforces
those recommendations. The screening modali-
ties addressedbyWHOand this guideline, include
cytology (also known as Papanicolaou, or Pap,
test), visual inspection (eg, visual inspection with
acetic acid [VIA]), and HPV DNA testing (screen-
ing). For evaluation of positive results, the WHO
guidelines include colposcopy, and for treatment,
the guidelines recommend loop electrosurgical
excision procedure (LEEP) of the transformation
zone and ablative treatments. The screening tests
are sometimes used and have been studied alone
and in combination. This ASCO guideline also
addresses screening in the vaccination era, self-
sampling, and emerging screening technologies.
In some settings that have establishedmass screen-
ing, cytology is the primary screeningmode; in other
settings, providers addHPVDNA testing (cotesting).
Some countries and regions are moving toward or
have adopted primary HPV DNA testing or VIA.5,6
In low-resource settings, where screeningmay not
currently be available, there is usually a shortage
ofpathologists, laboratories,colposcopistsandother
health providers, which limits the establishment of
a traditional screening program. For example, some
countries in sub-Saharan Africa have no patholo-
gists7,8 and/or laboratories.9 However, HPV DNA
testing, which is more effective than the traditional
cytology screening test, may be introduced without
pathology and laboratories. Therefore, less infra-
structure is needed compared with cytology test-
ing10 (see Cost and Policy Implications).
As HPV vaccination becomes more widespread
and the rate of HPV infection decreases, public
health authorities must decide on screening pol-
icies. Although prophylactic HPV vaccinationmay
be the ultimate cervical cancer prevention strategy,
current HPV vaccines prevent infections but do
not treat pre-existing infections and conditions.11,12
Moreover, bivalent and quadrivalent HPV vac-
cines provide only partial protection against cer-
vical cancer. Therefore, even if universal female
HPV vaccination could be rapidly deployed, there
would still be several generations of at-risk,
HPV-infected women who would not benefit
from—and would unlikely be targeted for—HPV
vaccination. Without robust screening, millions of
women will die of cervical cancer before the impact
of HPV vaccines on cervical cancer is observed.3
Thus, secondary prevention by cervical cancer
screening will be needed for the foreseeable
future. (See Special Commentary on vaccination
and screening for an in-depth discussion.)
The diagnosis of cervical cancer precursors is
based on the pathologist’s judgment of the thick-
ness of the transformed epithelium in biopsied or
excised tissue, which is graded (in order of in-
creasing severity) as negative or as cervical intra-
epithelial neoplasia (CIN) grade 1 (CIN1; up to
one-third thickness of epithelium), grade 2 (CIN2;
up to two-thirds thickness), or grade 3 (CIN3; two-
thirds thickness or greater). Other abnormal re-
sults may include atypical squamous cells (ASC),
ASC of undetermined significance (ASC-US), and
adenocarcinoma in situ (AIS), the glandular equiv-
alent of CIN3 and the precursor to adenocarci-
noma. In this guideline, the termprecursor lesions
refers to CIN2 or greater (> CIN2), defined as a
diagnosis of CIN2 (the standard-of-care thresh-
old that triggers treatment), CIN3, or AIS. CIN1 is
not considered a precursor lesion; most cases of
CIN1 regress within 6 years.13 CIN2 is considered
an equivocal precancerous diagnosis; that is, some
instances of CIN2 are CIN1 or HPV infection,14 and
therefore, treatment of all CIN2 may represent
overtreatment.15
ASCO has established a process for resource-
stratified guidelines, which includes mixed methods
of guideline development, adaptation of the clinical
practice guidelines of other organizations, and
formal expert consensus. This article summa-
rizes the results of that process and presents
resource-stratified recommendations that are
based, in part, on formal consensus and adap-
tation from existing guidelines on the screen-
ing, triage of screening results, and treatment
of women with cervical cancer precursor lesions
(these guidelines are listed in Results and Ap-
pendix Table A2).
ASCO uses an evidence-based approach to in-
form guideline recommendations. In developing
resource-stratified guidelines, ASCO has adopted
its framework from the four-tier approach (basic,
limited, enhanced, maximal; Table 1) developed
by the Breast Health Global Initiative and made
modifications to that framework on the basis of
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the Disease Control Priorities 3.16,17 Separate
ASCO resource-stratified guidelines provide guid-
ance on the treatment of women with invasive
cervical cancer2 and on primary prevention
(forthcoming).
GUIDELINE QUESTIONS
This clinical practice guideline addresses the
following four overarching clinical questions: (1)
What is the best method(s) for screening for
each resource stratum? (2) What is the best triage
strategy for women with positive results or other
abnormal (eg, discordant HPV/cytology) results?
(3) What are the best management strategies for
women with precursors of cervical cancer? (4)
What screening strategy should be recommended
for women who have received HPV vaccination?
METHODS
These recommendations were developed by an
ASCO Expert Panel with multinational and multi-
disciplinary representation (Appendix Table A1).
The Expert Panel met via teleconference and in
person and corresponded through e-mail. On the
basis of the consideration of the evidence, the
authors were asked to contribute to the develop-
ment of the guideline, provide critical review, and
finalize the guideline recommendations. Members
of the Expert Panel were responsible for reviewing
andapproving thepenultimate versionof theguide-
line, which was then circulated for external review
and submitted to a peer-reviewed journal for edito-
rial review and consideration for publication. This
guideline was partially informed by ASCO’s modified
Delphi Formal Expert Consensusmethodology, dur-
ing which the Expert Panel was supplemented by
additional experts recruited to rate their agreement
with thedraftedrecommendations.Theentiremem-
bership of experts is referred to as the Consensus
Panel (DataSupplementprovidesa listofmembers).
All ASCO guidelines are ultimately reviewed and
approved by the Expert Panel and theASCOClinical
Practice Guideline Committee before publication.
The guideline development process was also
informed by the ADAPTE methodology as an
alternative to de novo recommendation devel-
opment. Adaptation of guidelines is considered
by ASCO in selected circumstances, when one or
more quality guidelines from other organizations
already exist on the same topic. The objective of
the ADAPTE process is to take advantage of exist-
ing guidelines to enhance efficient production,
reduce duplication, and promote the local uptake
of quality guideline recommendations.
The ASCO adaptation and formal expert consen-
sus processes begin with a literature search to
identify literature including candidate guidelines
for adaptation. The panel used literature searches
(from 1966 to 2015, with additional searches for
literaturepublished inspecificareas),existingguide-
lines and expert consensus publications, some lit-
erature suggested by panel members, and clinical
experience as guides.
Adapted guideline manuscripts are reviewed and
approved by the Clinical Practice Guideline Com-
mittee. The review includes the following two parts:
methodologic review and content review. The
Table 1 – Four-Tiered Resource Settings for Secondary Prevention
Setting Definition
Basic Core resources or fundamental services absolutely necessary for any public health/
primary health care system to function; basic-level services typically are applied in
a single clinical interaction; screening is feasible for highest need populations.
Limited Second-tier resources or services thatproducemajor improvements inoutcomes, suchas
incidence and cost effectiveness, but that are attainable with limited financial means
and modest infrastructure; limited-level services may involve single or multiple
interactions; universal public health interventions are feasible for a greater percentage
of the population than primary target group.
Enhanced Third-tier resources or services that are optional but important; enhanced-level resources
may produce further improvements in outcomebut increase the number and quality of
screening/treatmentoptionsand individual choice (perhapsability to trackpatientsand
links to registries).
Maximal Mayusehigh-resource setting guidelines; high-level/state-of-the art resources or services
that may be used in some high-resource countries and/or may be recommended by
high-resource setting guidelines that do not adapt to resource constraints; this should
be considered lower priority than in the other settings on the basis of cost impracticality
for limited-resource environment.
NOTE. Data adapted.16,17
5 jgo.ascopubs.org JGO – Journal of Global Oncology
Downloaded from ascopubs.org by Queen Mary and Westfield College on September 6, 2017 from 138.037.213.175
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
formerwascompletedby twoASCOstaffmembers
and the latter by members of the Expert Panel
convened by ASCO.
The guideline recommendations were crafted, in
part, using the Guidelines Into Decision Support
methodology and accompanying BRIDGE-Wiz soft-
ware (Yale, New Haven, CT).19 Detailed information




The ASCO Expert Panel and guidelines staff will
work with the Steering Committee to keep abreast
of any substantive updates to the guideline. On the
basis of the formal review of the emerging litera-
ture, ASCO will determine the need to update this
guideline.
This is the most recent information as of the
publication date. Visit the ASCO Guidelines Wiki
at (www.asco.org/guidelineswiki) to submit new
evidence.
Guideline Disclaimer
The clinical practice guidelines and other guid-
ance published herein are provided by ASCO to
assist providers in clinical decision making. The
information herein should not be relied upon as
being complete or accurate, nor should it be
considered as inclusive of all proper treatments
or methods of care or as a statement of the
standard of care. With the rapid development of
scientific knowledge, new evidence may emerge
between the time information is developed and
when it is published or read. The information is not
continually updated and may not reflect the most
recent evidence. The information addresses only
the topics specifically identified therein and is
not applicable to other interventions, diseases,
or stages of diseases. This information does not
mandate any particular course of medical care.
Furthermore, the information is not intended
to substitute for the independent professional
judgment of the treating provider, as the in-
formation does not account for individual var-
iation among patients. Recommendations reflect
high, moderate, or low confidence that the recom-
mendation reflects the net effect of a given course
of action. The use of words such as must, must
not, should, and should not indicates that a course
of action is recommended or not recommended for
either most or many patients, but there is latitude
for the treating physician to select other courses of
action in individual cases. In all cases, the selected
course of action should be considered by the
treating provider in the context of treating the indi-
vidual patient. Use of the information is voluntary.
ASCO provides this information on an as-is basis
and makes no warranty, express or implied,
regarding the information. ASCO specifically
disclaims any warranties of merchantability or
fitness for a particular use or purpose. ASCO
assumes no responsibility for any injury or dam-
age to persons or property arising out of or related
to any use of this information or for any errors or
omissions.
Guideline and Conflict of Interest
The Expert Panel was assembled in accordance
with ASCO’s Conflict of Interest Policy Implemen-
tation for Clinical Practice Guidelines (“Policy,”
foundat http://www.asco.org/rwc). Allmembers of
the Expert Panel completed ASCO’s disclosure
form, which requires disclosure of financial and
other interests, including relationships with com-
mercial entities that are reasonably likely to expe-
rience direct regulatory or commercial impact as a
result of promulgation of the guideline. Categories
for disclosure include employment; leadership;
stock or other ownership; honoraria; consulting
or advisory role; speaker’s bureau; research fund-
ing; patents, royalties, other intellectual property;
expert testimony; travel, accommodations, ex-
penses; and other relationships. In accordance
with the Policy, the majority of the members of the
Expert Panel did not disclose any relationships
constituting a conflict under the Policy.
RESULTS
Literature Search
As part of the systematic literature review, the
PubMed, SAGE, Cochrane Systematic Review,
andNational Guideline Clearinghouse databases
were searched for literature and guidelines,
systematic reviews, and meta-analyses that
were about screening for, or treatmentof, precursor
lesions; developed by multidisciplinary content ex-
perts as part of a recognized organizational effort;
and published between 1966 and 2015.
Literature searches based on prespecified criteria
aswell as updates of literature searcheswith terms
used by other guidelines were conducted, and a
title screen was completed and abstract review be-
gun.However, because several high- andmoderate-
quality guidelines were found, the full text review
and data extraction steps of the systematic review
were not completed.
Searches for cost-effectiveness analyses (CEAs)
were also conducted and titles, abstracts, and full
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texts were reviewed. Forty-one CEAs were found
(this guideline cites three from these results,20-22
andpanelmemberssuggestedanadditionalstudy23).
Articles were excluded from the systematic review if
they were meeting abstracts, books, editorials, com-
mentaries, letters, news articles, case reports, or
narrative reviews.
Methods and Results of the ASCO Updated
Literature Search
A search for new evidence was conducted by
ASCO guidelines staff to identify relevant randomized
clinical trials, systematic reviews,meta-analyses,
and guidelines published since the Cancer Care
Ontario (CCO) and WHO guidelines were com-
pleted. Following the strategies described in the
WHO guidelines, PubMed and EMBASE data-
bases were searched from 2011 to December
2014 in July 2015. The search was restricted
to articles published in English, and the ASCO
guideline inclusion criteria were applied to re-
view of the literature search results. Titles were
reviewed; as described earlier, evidence re-
views conducted for other societies’ guidelines
were used as the evidence base.
Sixteen guidelines were found in the search, and
their currency, content, and methodology were
reviewed. On the basis of content and methodol-
ogy assessments, the Expert Panel chose seven
guidelines as the evidentiary basis for the guideline
recommendations; these guidelines were from
the American Cancer Society (ACS)/American
Society for Colposcopy and Cervical Pathology
(ASCCP)/American Society for Clinical Pathology
(ASCP)24,25; a second ASCCP-led effort26; an-
other US-based multisociety group’s guideline,
referred to here as Huh et al6; CCO27; a European
guideline, referred to as von Karsa et al5; and two
guidelines from the WHO.28,29 (Note that at the
timeof thiswriting, theUSPreventiveServices Task
Force was updating its guidelines.30) Appendix
Table A2 contains links to these guidelines.
The existing guidelines cover different screening
tests, including cytology, visual inspection, and
HPV DNA testing; different modes of sam-
pling cervical cells (clinician and self-sampling);
different strategies when screening results are
abnormal, also known as triage; the screen-and-
treat strategy; the management of > CIN2; and
the follow-up of women after receiving treat-
ment of > CIN2, as well as secondary preven-
tion for women in subpopulations, such as those
with HIV.
This ASCO guideline reinforces selected recom-
mendations offered in the ACS/ASCCP/ASCP,
ASCCP, CCO, WHO, von Karsa et al,5 and Huh
et al6 guidelines and acknowledges the effort
put forth by the authors and aforementioned
societies to produce evidence- and/or consensus-
based guidelines informing practitioners and
institutions.
These guidelines were published between 2011
and 2015. Six were based completely or in part on
systematic reviews.5,24-29 TheWHO guideline has
the largest global constituency andmakes recom-
mendations for resource-constrained areas. All
the other guidelines were developed in maximal
resource–level settings. Various types and levels of
evidence were used to support these guidelines.
Randomized controlled trials (RCTs) have been
conducted on the type of test for primary screening
and the treatment of precursor lesions. Formost of
the other clinical questions, these guidelines were
based on nonrandomized comparative studies,
observational data, pooled analyses, modeling,
and expert opinion. Appendix Table A2 lists links
to and the Data Supplement provides an overview
of the guidelines, including information on their
clinical questions, target populations, development
methodology, and details of key evidence.
ASCO Methodologic Review
The methodologic review of the guidelines was
completed by two ASCO guideline staff members
using the Rigor of Development subscale of the
Appraisal of Guidelines for Research and Evaluation
II instrument.31 The score for the Rigor of Develop-
ment domain is calculated by summing the scores
across individual items in the domain and standard-
izing the total score as a proportion of the maximum
possible score. Detailed results of the scoring and
the Appraisal of Guidelines for Research and Eval-
uation II assessment process for this guideline are
available in the Methodology Supplement.
FINAL RECOMMENDATIONS
The recommendations were developed by a mul-
tinational, multidisciplinary group of experts using
evidence from existing guidelines, supplementary
literature, and clinical experience as guides. The
ASCOExpert Panel underscores that public health
officials and health care practitioners who imple-
ment the recommendations presented in this
guideline should first identify the available re-
sources in their local and referral facilities and
endeavor to provide the highest level of care
possible with those resources.
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Maximal-Resource Setting
In maximal-resource settings, cervical cancer
screeningwithHPVDNA testing should be offered
every 5 years from ages 25 to 65 years. On an
individual basis, women may elect to receive
screening until 70 years of age (Type: evidence
based for test, interval, and age [25 to 65 years];
Type: formal consensus based [until age 70 years];
Evidence quality: high; Strength of recommenda-
tion: strong).
Women who are> 65 years of age who have had
consistently negative screening results during the
past > 15 years may cease screening. Women
who are 65 years of age and have a positive result
after age 60 should be reinvited to undergo
screening 2, 5, and 10 years after the last pos-
itive result. If women have received no or irreg-
ular screening, they should undergo screening
once at age 65 years, and if the result is negative,
they should exit screening (Type: evidence
based; Evidence quality: intermediate; Strength
of recommendation: moderate).
If the results of the HPV DNA test are positive,
clinicians should then perform triage with reflex
genotyping forHPV16/18 (withorwithoutHPV45)
and/or cytology as soon as HPV test results are
known (Type: evidence based; Evidence quality:
high; Strength of recommendation: strong). If tri-
age results are abnormal (ie,>ASC-US or positive
for HPV 16/18 [with or without HPV 45]), women
should be referred to colposcopy, during which
biopsies of any acetowhite (or suggestive of can-
cer) areas should be taken, even if the acetowhite
lesion might appear insignificant. If triage results
are negative (eg, primary HPV positive and cytology
triage negative), then repeat HPV testing at the
12-month follow-up (Type: evidence based; Evi-
dence quality: intermediate; Strength of recom-
mendation: strong).
If HPV test results are positive at the repeat
12-month follow-up, refer women to colposcopy.
If HPV test results are negative at the 12- and
24-month follow-ups or negative at any consecu-
tiveHPV test 12monthsapart, thenwomenshould
return to routine screening (Type: evidencebased;
Evidence quality: high; Strength of recommenda-
tion: strong).
Women who have received HPV and cytology
cotesting triage and have HPV-positive results
and abnormal cytology should be referred for
colposcopy and biopsy. If results are HPV pos-
itive and cytology normal, repeat cotesting at
12 months. If at repeat testing HPV is still pos-
itive, patients should be referred for colposcopy
and biopsy, regardless of cytology results (Type:
formal consensus based; Evidence quality: inter-
mediate; Strength of recommendation: strong).
If the results of the biopsy indicate that women
have precursor lesions (> CIN2), then clinicians
should offer LEEP (if there is a high level of quality
assurance [QA]),32 or where LEEP is contraindi-
cated, ablative treatments may be offered. (Type:
evidence based; Evidence quality: high; Strength
of recommendation: strong).
After women receive treatment of precursor le-
sions, follow-up should consist of HPV DNA testing
at 12 months. If 12-month results are positive,
continue annual screening; if not, return to rou-
tine screening (Type: formal consensus based;
Evidence quality: intermediate; Strength of rec-
ommendation: moderate).
Source guidelines and discussion. The age range
for HPV testing was modified from guidelines by
Huh et al6 that based the age of initiation on the
Addressing the Need for Advanced HPV Diagnos-
tics (ATHENA) RCT used for US Food and Drug
Administration registration.33 Adding the years 25
to 29 to the starting age recommended by CCO
and WHO (30 years) is from the evidence that
HPV testing benefits women who are HPV neg-
ative, including those age 25 to 29 years.6
Screening is not recommended for women un-
der the age of 25 given the lack of evidence of the
benefit of decreased cancer risk and the poten-
tial harms of screening and overtreatment. For
example, as described in the Huh et al6 guideline,
there is a lower 3-year cumulative incidence rate
for women whose results were high-risk HPV
type (hrHPV) negative. The age of cessation at
65 years is suggested on the basis of existing
guidelines. In general, the criteria for exiting
screening are determined primarily on resource
availability and the average life span of women in
each setting, which is matched with the current
knowledge of the HPV infection-to-dysplasia
process. As life expectancy in maximal resource
settings (eg, Organization for Economic Coop-
eration and Development countries) increases,
and where estimated incidence rates for women
ages 60 to 64 and 65 to 69 years are similar
(16.6 and 16.1 per 100,000, respectively),1 women
and their doctors may make individualized de-
cisions to extend screening up to 70 years of age.
For example, women who are 65 to 70 years old,
have received screening, and have a history of
positive screening (HPV, cytology, or VIA) test
results in the last 5 years may be reinvited to
screening until 70 years of age.
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The choice of HPV DNA testing is supported by
evidence of its effectiveness as a screening test
and by several existing guidelines from developers
including WHO, von Karsa et al,5 Huh et al,6 and
CCO. HPV DNA testing is more sensitive than
cytology.6 The interval of 5 years is based on the
WHO, CCO, and European guidelines (CCO rec-
ommendations were specific to women older than
age 30 years). There have been 10 RCTs on pri-
mary HPV testing. (The CCO guideline cites seven
RCTs published between 2007 and 2010, includ-
ing New Techniques in Cervical Cancer [NTCC], A
Randomized Controlled Trial of HPV Testing in
PrimaryCervicalScreening[ARTISTIC],Population-
Based Screening Study Amsterdam [POBASCAM],
Swedescreen, Finnish Public Health Trial [FPHT],
Sankaranarayanan et al, and Canadian Cervical
Cancer Screening Trial [CCCaST].27) The Huh
et al6 guidance cites pooled analyses of European
RCTs (Dillner et al,34 which included seven pro-
spective studies, andRoncoet al,35which included
four of the trials in CCO that had data from
two rounds of screening [ARTISTIC, POBASCAM,
NTCC, and Swedescreen published between
2007 and 2012]), the Vrije Universiteit Medi-
cal Centre-Saltro (VUSA)-Screen study,36 the
ATHENA RCT, and a Kaiser database. Ronco
et al35 mentioned FOCAL, listed as ongoing by
CCO, which was not included in the Huh et al6
guidance. Selected RCT data have been extract-
ed in the Data Supplement.
Cotesting is an option, as recommended by the
ACS/ASCCP/ASC pathology guideline; however,
the added value on the basis of increased costs
is limited. Evidence for this statement is found in
the Huh et al6 guideline and a 2014 publication
including CEA from the ARTISTIC trial, which
found that strategies using primaryHPV screening
were more cost-effective than those using cotest-
ing (eg, the rate of primary HPV screening with
cytology triage and repeat HPV at 12 or 24months
was 22% for vaccinated cohorts and 18% in un-
vaccinated cohorts).37,38
In maximal-resource settings, mass screening
should be available to the entire target population
andshouldaim tocoverat least80%ofwomenage
25 to 70 years. Readers should note that there are
more than 100 molecular tests for the detection
of HPV; however, population-based screening
programs should only use HPV tests that show
clinical utility (which ASCO considers the highest
level of evidence for biomarkers39), are properly
validated,40,41 and are approved by national
and/or international regulatory agencies, such
as US Food and Drug Administration approval,
European Union CE marking, WHO endorsement/
prequalification, or other country- or regional-level
regulatory agencies. The tests should also have
confirmed good manufacturing practices.
Women who are 65 to 70 years of age and do not
have a history of> CIN3 do not need to be offered
screening if they have had two or more consecu-
tive negative HPV test results or three or more
negative cytology test results andonly negative test
results in the past 15 years.
If there are positive results from colposcopy, the
options for the treatment of women with precursor
lesions include LEEP, which is the first choice in
maximal and enhanced settings, and various ab-
lative treatments including cryotherapy, cold co-
agulation, or laser, which should all meet a high
level of QA metrics (listed in Table 2).29,32 Cryo-
therapy is not recommended in the maximal set-
ting. LEEP is preferred, in part, because it provides
tissue for a histopathologic diagnosis. However,
LEEP technology and trainingmaynot be available
in lower resource settings and/or have contraindi-
cations. The Massad et al26 and WHO guidelines,
citing RCTs and Cochrane reviews, and a more
recent (2013) Cochrane review42 showed mini-
mal differences between treatments. The WHO
guideline states there is low evidence of treatment
versus no treatment, mostly pooled results of non-
comparative, nonrandomized studies. There are
no RCTs specifically on HPV after LEEP.43 There
is a paucity of prospective, comparative data on
other treatment and follow-up strategies to guide
recommendations on post-treatment follow-up.26
Therefore, on the basis of formal consensus, this
guideline recommends follow-up HPV DNA test-
ing at 12 months after one of these treatments.
Enhanced-Resource Setting
In enhanced-resource settings, cervical cancer
screeningwithHPVDNA testing should be offered
to women 30 to 65 years of age every 5 years (ie,
second screen 5 years from the first; Type: evi-
dence based; Evidence quality: high; Strength of
recommendation: strong). If there are two consec-
utive negative screening test results, subsequent
screening should be extended to every 10 years
(Type: formal consensus based; Evidence quality:
intermediate-low; Strength of recommendation:
moderate).
Women who are> 65 years of age who have had
consistently negative screening results during
the past> 15 yearsmay cease screening.Women
who are 65 years of age and have a positive result
after age 60 years should be reinvited to undergo
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screening 2, 5, and 10 years after the last positive
result. If women have received no or irregular
screening, they should undergo screening once
at age 65 years, and if the result is negative, they
should exit screening (Type: formal consensus
based; Evidence quality: low; Strength of recom-
mendation: weak).
If the results of the HPV DNA test are positive,
clinicians should then perform triage with HPV
genotyping forHPV16/18 (withorwithoutHPV45)
and/or reflex cytology (Type: evidence based; Ev-
idencequality: high; Strengthof recommendation:
strong). If triage results are abnormal (ie, > ASC-
US or positive for HPV 16/18 [with or without HPV
45]), women should be referred to colposcopy,
during which biopsies of any acetowhite (or sug-
gestive of cancer) areas should be taken, even if
the acetowhite lesionmight appear insignificant. If
triage results are negative (eg, primary HPV pos-
itiveandcytology triagenegative), then repeatHPV
testing at the 12-month follow-up (Type: evidence
based; Evidence quality: intermediate; Strength of
recommendation: strong).
If HPV test results are positive at the repeat
12-month follow-up, refer women to colposcopy.
If HPV test results are negative at the 12- and
24-month follow-ups or negative at any consecutive
HPVtest12monthsapart, thenwomenshould return
toroutinescreening(Type:evidencebased;Evidence
quality: high; Strength of recommendation: strong).
If the results of colposcopyandbiopsy indicate that
women have precursor lesions (> CIN2), then
clinicians should offer LEEP (if there is a high level
of QA) or, where LEEP is contraindicated, ablative
treatmentsmay be offered (Type: evidence based;
Evidence quality: high; Strength of recommenda-
tion: strong). After women receive treatment of
precursor lesions, follow-up should consist of HPV
DNA testing at 12months. If 12-month results are
positive, continue annual screening; if not, return
to routine screening (Type: formal consensus
based; Evidence quality: intermediate; Strength
of recommendation: moderate).
Source guidelines and discussion. In enhanced-
resource settings, which refer to most programs
in urban areas of middle-income countries, pub-
lic health authorities may narrow the screening
age range to 30 to 65 years; this is in agreement
with the CCO guidelines. There is insufficient evi-
dence on the best age of cessation.44 The exten-
sion to 10 years after negative tests is based on
the von Karsa et al5 guideline.
The cost analysis study by Beal et al21 (2014) was
conducted from theperspective ofMexicanhealth
care institutions and compared the following four
screening plus triage strategies: cytology alone,
hrHPV with reflex cytology, hrHPV with molecular
triage, and cotesting with molecular triage. The
study found that when the base case was cytology
alone, hrHPV with molecular triage had the low-
est incremental cost-effectiveness ratio (ICER)
(–819 v –108.99 v –537 for hrHPVwithmolecular
triage, hrHPV with cytology triage, and cotesting,
respectively), with a cost at US$91.5 million (2013
US dollars). This strategy resulted in fewer women
undergoing colposcopy. (Note that Mexico’s 2013
gross national income per capita was $15,620
[WorldBankdata,grossnational incomepercapita,
purchasing power parity].45)
As with the maximal-resource setting recommen-
dations, if a womanhas a history of positive screen-
ing (HPV, cytology, or VIA) test results in the past
5 years, she should be reinvited to screening. The
interval may increase to 10 years in enhanced set-
tings after two negative tests and is a modification
of the von Karsa et al5 guidelines, which give the
upper limit of 10 years after a negative test. This is
also because HPV testing in older women yields a
higher specificity.46 In the enhanced setting, if HPV
Table 2 – Quality Assurance Criteria for Treatment of Precursor Lesions
Treatment Modality Criteria Source
LEEP The results of VIA or VILI or colposcopy
positive, not suspicious for cancer unless
LEEP for biopsy and not treatment, can
identify full extent of external lesions, etc,
. 12 weeks postpartum
Jhpiego32
Sufficient training of provider, with ability to
handle complications
WHO4
Absolute contraindications to LEEP ASCO Expert Panel
Pregnancy
Acute cervicitis
Bleeding or coagulation disorders
Patient unwillingness
Relative contraindications to LEEP
Patient , 3 months postpartum
Recurrence in a postcervical conization
case
Young patient with a small cervix
Strong suspicion of microinvasive cancer
Ablation Lesion covers , 75% of cervix, lesion does
not enter endocervical canal, patient does
not have positive ECC, entire lesion can be
visualized and covered by the cryotherapy
probe, no suspicion for invasive cancer
WHO29
Abbreviations: ECC, endocervical curettage; LEEP, loop electrosurgical excision procedure;VIA, visual
inspection with acetic acid; VILI, visual inspection with Lugol’s iodine.
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genotyping is available, use this for triage. If HPV
genotyping is not available, reflex cytology may be
used, because the low predictive value of a pos-
itive HPV DNA test for finding > CIN2 can be
raised to the level of cytology by cytologic triage of
HPV-positive women.47,48 Cytology for triage is
recommended by the CCO and von Karsa et al5
guidelines.
Follow-up after triage is the same as in maximal-
resource settings. For management of precursor
lesions, theExpert Panel recommendsusing LEEP
as a first choice, but if LEEP is not available or
is contraindicated and the patient is eligible for
ablation (Table 2),29 then the clinician may use
ablation. The other recommendations are the
same as in the maximal setting.
Limited-Resource Setting
Cervical cancer screening with HPV DNA testing
should be offered to women age 30 to 49 years
every 10 years, corresponding to two to three times
per lifetime (Type: evidence based [age range],
Type: formal consensus based [interval]; Evidence
quality: intermediate; Strength of recommenda-
tion: moderate).
If the results of the HPV DNA test are positive,
clinicians should then perform triage with reflex
cytology (quality assured) and/or HPV genotyping
for HPV 16/18 (with or without HPV 45) or with
visual assessment for treatment (VAT; for cytology
and genotyping: Type: evidence based; Evidence
quality: high;Strengthof recommendation: strong;
for VAT: Type: formal consensus based; Evidence
quality: low; Strength of recommendation: weak).
If cytology triage results are abnormal (ie,> ASC-
US), women should be referred to quality-assured
colposcopy (the first choice, if available and ac-
cessible), duringwhich biopsies of any acetowhite
(or suggestive of cancer) areas should be taken,
even if the acetowhite lesion might appear in-
significant. If colposcopy is not available, then
perform VAT (Type: evidence based; Evidence
quality: intermediate; Strength of recommenda-
tion: moderate).
If HPV genotyping or VAT triage results are posi-
tive, then women should be treated. If the results
from both of these forms of triage are negative,
then repeatHPV testing at the 12-month follow-up
(Type: evidence based; Evidence quality: high;
Strength of recommendation: strong). If test re-
sults arepositive at the repeat 12-month follow-up,
then women should be treated (Type: formal
consensus based; Evidence quality: intermedi-
ate; Strength of recommendation: moderate).
For treatment, clinicians should offer ablation
if the criteria are satisfied; if not and resources
are available, then offer LEEP (if there is a high
level of QA; Table 2; Type: evidence based;
Evidence quality: high; Strength of recommen-
dation: strong). After women receive treatment
of precursor lesions, follow-up should consist
of the same testing at 12 months (Type: formal
consensus based; Evidence quality: intermedi-
ate; Strength of recommendation: moderate).
CEAs. The interval of 10 years (three times per
lifetime) is supported by a CEA23 found in ASCO’s
literature search for CEAs and was based on data
fromdemonstrationprojects in SouthAsia, Central
America, and East Africa. The objective of this
study was analyzing cost-effectiveness of vari-
ous tests (HPV DNA test, VIA, and cytology),
age ranges, screening intervals, and numbers of
screens per lifetime in limited-resource settings.
This analysis supported the WHO guidelines for
the age range of 30 to 49 years and found that
HPV DNA testing three times per lifetime every
10 years starting at age 30 was a cost-effective
strategy with attractive ICERs of 350 to 580 (inter-
national dollars) per life-year saved (LYS), varying
by region. Cost of screening three times per
lifetime with intervals of 5 years ranged from
$180 to $1,600 international dollars per LYS
(starting at age 30 years in India and at age
25 years in Uganda).23
Source guidelines and discussion. In limited-
resource settings, which often correspond to rural
areas in middle-income countries, most of the
recommendations are based on the WHO guide-
line. The triage of positive screening results will
depend on resources and the sample available
from the screening. If there is sufficient sample
from the primary test and genotyping is available
or if genotyping is concurrent, that should be
used, as recommended by the Huh et al6 guide-
line. If not and if cytology meets QAmetrics,5 that
may be used. If cytology does not meet the QA
metrics, then VAT should be used, as recom-
mendedbyWHO.28 If cytology results arepositive,
then women may receive quality-assured colpo-
scopy, if available; otherwise, see and treat on the
basis of the triage results. Although it was not within
the scope of this guideline to develop de novo or
formally review others’ recommendations on QA for
colposcopy, groups that have addressed this in-
clude theNationalHealth Service49 and theSociety
of Canadian Colposcopists.50 In addition, the 2011
International Federation for Cervical Pathology and
Colposcopy Nomenclature is used worldwide.51
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If a woman has a history of abnormalities (eg,
repetitively HPV-positive results) and recalling
women for follow-up after abnormal results is a
challenge, the womanmight have an elevated risk
for > CIN2, and it might be cost-effective to offer
treatment in limited or basic settings. (However, in
enhanced and maximal settings, when recall is
more feasible, further tests should be performed
before treatment.)
The recommendation to follow-up other results if
HPV genotyping is not available is a modification
of CCO and WHO recommendations. The man-
agement of precursor lesions is based on the
ASCCP26andWHOguidelines29; the latter supports
performing LEEP. On the basis of each authority
that provides screening CEA, women older than
age 49 years with no previous screening may be
offered screening, after the priority age group (30 to
49 years) is covered.
Basic-Resource Setting
If HPV DNA testing for cervical cancer screening
is not available, thenVIA shouldbeofferedwith the
goal of developing health systems and moving to
population-based screening with HPV testing at
the earliest opportunity. Screening should be of-
fered to women age 30 to 49 years at least once per
lifetime but not more than three times per lifetime
(Type: evidence based; Evidencequality: interme-
diate; Strength of recommendation: strong). If the
results of available HPV testing are positive, clini-
cians should then perform VAT followed by treat-
ment with cryotherapy and/or LEEP, depending
on the size and location of the lesion (Type: for-
mal consensus based; Evidence quality: low;
Strength of recommendation: moderate). If pri-
mary screening is VIA and results are positive, then
treatment shouldbeofferedwith cryotherapyand/or
LEEP, depending on the size and location of the
lesion (Type: evidence based; Evidence quality:
intermediate52; Strength of recommendation:
moderate).
Afterwomen receive treatment of precursor lesions,
then follow up with the available test at 12 months.
If the result is negative, then women should return to
routine screening (Type: formal consensus based;
Evidence quality: intermediate; Strength of recom-
mendation: moderate).
CEAs. In addition to the study by Campos et al23
discussed in limited-setting recommendations,
the study by Shi et al20 (found in ASCO literature
search for CEAs) was a CEA that involved several
substudies that compared HPV versus VIA versus
VIA/visual inspection with Lugol’s iodine once or
twice per lifetime or at routine intervals for primary
testing in rural China. The outcomes included
cost-effectiveness, incidence, mortality, and opti-
mal age ranges. The investigators found that the
lowest cost-effectiveness ratio (CER) for screening
(compared with no intervention) was associated
with VIA once per lifetime at age 35 years, and the
second lowest was with VIA twice per lifetime (at
age35 to 45 years). The average lifetime reduction
in cancer mortality was 8% for once per lifetime for
VIA and 12% for HPV; twice per lifetime reductions
were 16% and 24%, respectively. “Depending on
the test technology used, and assuming a partic-
ipation rate of approximately 70%, we found that
once-lifetime screening at age 35 years would
reduceage-standardisedcervical cancermortality
in the population by 8-12% over the long term,
with a CER of $557-959 per LYS. Regular screen-
ing at a feasible age-standardised participation
rate of 62% in women aged 30-59 years would
reduce cervical cancer mortality by 19-54%,
with a CER of $665-2,269 per LYS.”20(p14) (The
World Bank currently categorizes China as an
upper-middle-income economy.53)
Source guidelines and discussion. These recom-
mendations are based on the WHO guideline. In
basic settings, where there is no mass screening
andnoculture of screening, VIAmaybeused,with
the goal of moving to population-based screening
with HPV testing at the earliest opportunity. There
have been mixed results regarding VIA as primary
screening. A clusterRCTonVIA involving151,538
women in India was published after the WHO
guidelines.54 Outcomes including cervical cancer
mortality and incidence for 75,630 women re-
ceiving four rounds of VIA plus cancer education
were compared with those of 76,178 women re-
ceiving cancer education alone. The authors have
published 12 years of follow-up. Age-adjusted
rates (AARs) for incidence of cervical cancer were
29 (95% CI, 24.5 to 33.4) for VIA plus education
compared with 29.4 (95% CI, 27.2 to 31.7) for
educationalone(incident rateratio,0.8-1.2;P5 .79).
AARs for cervical cancer mortality were 14.4 (95%
CI, 12.7 to 16.2) for VIA plus education compared
with 19.8 (95% CI, 17.8 to 21.8) for education
alone, with an incident rate ratio of 0.69 (95% CI,
0.54 to 0.88; P 5 .003). All-cause mortality AARs
were 1,340.5 (95% CI, 1,321.2 to 1,359.6) for VIA
plus education compared with 1,391.3 (95% CI,
1,372.1 to 1,410.4) for education alone, and the
mortality rate ratio was 0.93 (95% CI, 0.79 to 1.1;
P5 .41). (All figureswere for100,000person-years
of observation.)54 An earlier four-arm cluster
RCT conducted in India compared HPV testing,
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cytology, VIA, and standard care; it was published
with 8 years of follow-up.55 In that study, the sta-
tistically significant outcomes were in the HPV
testing arm, but not in the VIA arm. The hazard
ratio for mortality was 0.52 (95% CI, 0.33 to 0.83)
with HPV versus control. The hazard ratios for the
incidence of stage II or higher cervical cancer were
0.47 (95% CI, 32 to 0.69) for HPV versus control
and 1.04 (95% CI, 0.72 to 1.49) for VIA versus
control.
Screening with VIA helps build infrastructure and
brings women into medical care and screening
(eg, in Bangladesh and Tamil Nadu, India).56,57 If
screening is not started, the infrastructure will not
develop for HPV testing. This is recommended
while recognizing that follow-up opportunitiesmay
be limited. Regions should build toward having
systems in place to diagnose and treat women
with positive results and invasive cancer. For public
health entities that initiate VIA for primary screen-
ing, it is crucial to invest significant effort to use
validated training andvalidationprocedures. These
entitiesmust haveaplan for quality control of trained
VIA evaluators’ performance.
After the establishment of such patterns, public
health systems can introduce HPV testing. As these
systemsdevelop infrastructure for population-based
screening, parallel development of systems for di-
agnosis and treatment of invasive cancer needs to
occur.Concurrentlywith thedevelopmentof screen-
ing programs, programs should develop the capac-
ity toassesswomenwithsymptoms, includingwomen
outside of the target age range. In addition, the in-
troduction of VIA screeningmay lead to identification
of symptoms and women with symptoms seeking
care. There may be high levels of screen-detected
cancers on the first round of screening (many pre-
sumably in symptomatic women). Downstaging can
be valuable too if treatment is available. The recom-
mendations for age range, screening interval, tri-
age, andspecial populations in thebasic setting are
modifications of the WHO recommendations.28
Follow-up of abnormal results and treatment of
women with > CIN2 follow the WHO recommen-
dations on this condition.29
Recommendations for Special Populations
Recommendation SP1a: Women who are HIV
positive. Women who are HIV positive should
begin screening with HPV testing, every 2 to
3 years, as soon as they receive an HIV diagno-
sis. The recommended frequency depends on
the resource level; in general, it should be twice
as many times in a lifetime as in the general
population (Type: formal consensus based;
Evidence quality: low; Strength of recommenda-
tion: weak).
The recommended frequencies, according to re-
source setting, are as follows:
·Maximal: Women should be screened for
HPV approximately every 2 to 3 years.
·Enhanced: Women should be screened for
HPV at intervals of 2 to 3 years, then, if
negative, every 5 years (approximately eight
screenings per lifetime).
·Limited: Women should be screened for
HPV at intervals of every 2 to 3 years and
twice as many times in a lifetime as in the
general population (approximately four to
six screenings per lifetime).
·Basic: If HPV testing is available, womenwith
HIV should be screened for HPV as early as
possible starting at age 25, every 3 years if
the test results are negative initially; ap-
proximately twice per lifetime. If HPV testing
is not available, use VIA at the same intervals
(Type: evidence-based; Evidence quality:
low; Strength of recommendation: weak).
The management of abnormal results of screening
for women with HIV and positive results of triage
is the same as in the general population (Type:
formal consensus based; Evidence quality: low;
Strength of recommendation: moderate).
Recommendation SP1b: Women who are
immunosuppressed—all settings. Women who
are immunosuppressed for any reason other
than HIV should be offered the same screening
as women who are HIV positive (Type: formal
consensus based; Evidence quality: insuffi-
cient; Strength of recommendation: weak).
Discussion of SP1a and SP1b. There is insufficient
evidence regarding screening women with HIV;
only theWHOguidelinemadespecific recommen-
dations regarding thesewomen. There are no data
to informscreening forwomenwhoare immunosup-
pressed for other reasons. In general, these recom-
mendations agreewith theWHOguidelines,with the
grateful acknowledgment of thepanel.52 In addition,
Forhanet al58performedasystematic reviewonsee-
and-treat strategies for women with HIV in LMICs
and found a lack of long-term outcome data (includ-
ing morbidity and mortality and some HIV-specific
outcomes). All the studies found in the systematic
review by Forhan et al58 were observational.
Further, Vanni et al59 used a model-based ap-
proach to compare 27 strategies of primary HPV
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testing or cytology with triage of cytology, HPV, or
colposcopy, and each of these combinations at
6 months, 1 year, or 2 years, for women with HIV
inBrazil, which is characterized as amiddle-income
country. The authors found that once-yearly HPV
testing with cytology triage would be the most cost-
effective strategy for women with HIV in Brazil with
CER results ofUS$4,911per LYS,with the threshold
of Brazil’s per capita gross domestic product of
US$8,625 per LYS.59 (The World Bank currently
categorizes Brazil as an upper-middle-income
economy.53)
RecommendationSP2a:Womenwhoarepregnant—
all settings. Pregnant women should not receive
screening.
Recommendation SP2b: Women who are
postpartum—all settings. Women who are post-
partum should be screenedwith VIA 6 weeks after
delivery in basic settings. In other settings, HPV
testing is recommended 6 months after delivery,
unless there is uncertainty about completion of
follow-up, inwhichcase screening at 6weeks after
delivery is advised (Type for both: formal consen-
sus based; Evidence quality: insufficient; Strength
of recommendation: weak).
Discussion of SP2a and SP2b. There is no evi-
dence available to support evidence-based rec-
ommendations for women who are pregnant or
postpartum; therefore, the recommendations are
based on formal consensus. There is some in-
dication that as a result of immunechangesduring
pregnancy, some pregnant women may have in-
creasedHPV, which can subside after pregnancy.
Performing HPV testing during this time of eleva-
tion may then produce inaccurate results. The test
specificity increases with time. However, in some
settings, loss to follow-up may be a concern, and
becausewomenmayalready be seeing clinicians
for a postpartum and/or new baby visit at 6 weeks,
the recommendation presents an opportunity to
screen when the likelihood of a 6-month visit is
low. Providers can discuss the potential risks, in-
cluding opportunity costs, and benefits of screening
with pregnant women to help reach individual
decisions.
Recommendation SP3: Women who have had
hysterectomies (with no history of ‡ CIN2). In
all settings, screening may be discontinued in
women who have received a total hysterectomy
for benign causes with no history of cervical dys-
plasia or HPV. Women who have received a sub-
total hysterectomy (with an intact cervix) should
continue to receive routine screening (Type:
evidence-based; Evidence quality: high; Strength
of recommendation: strong).
Discussion of SP3. The recommendation regard-
ing women who have had hysterectomies was
adapted from the 2011 CCO interim recommenda-
tionsand the2012ACS/ASCCP/ASCPguidelines24,27
that state that no screening is necessary for women
who have undergone hysterectomy with cervix re-
moval and have had no history of> CIN2 within the
past 20 years. The ACS/ASCCP/ASCP recommenda-
tion on screening for vaginal cancer was based on
observational data.
SPECIAL COMMENTARY
What Is the Role of Self-Collection (Only for HPV
Molecular Testing)?
For improving coverage of screening, there
is evidence emerging or under way on self-
collection (also known as self-sampling). Self-
collected (self-sampled) specimensmay be used,
with a validated collection device, transport con-
ditions, and assay, as an alternative to provider-
collected specimens for HPV testing. Triage and
follow-up must be performed according to the
setting and resources available. An ASCO litera-
ture search found three systematic reviews and/or
meta-analyses on self-collection. A meta-analysis
by Arbyn et al60 found that “[t]he pooled sensitivity
ofHPV testingonself-sampleswas lower thanHPV
testing on a clinician-taken sample (ratio 0.88
[95% CI 0.85 to 0.91] for CIN2 or worse and
0.89 [0.83 to 0.96] for CIN3 or worse). In addi-
tion, specificity was lower in self-samples versus
clinician-taken samples (ratio 0.96 [0.95 to 0.97]
for CIN2 or worse and 0.96 [0.93 to 0.99] for
CIN3 or worse).”60(p127) There is a significant
difference in the sensitivity of self-sampling versus
cervical sampling when a signal amplification test
is used, but that difference is minimal or null
when a polymerase chain reaction–based test is
used. A systematic review and meta-analysis by
Racey et al61 found that relative compliance was
higher with home-based self-collection HPV DNA
testing kits than with standard clinic-based cytol-
ogy. An earlier systematic review by Stewart et al62
found high acceptability by women performing
self-collection.
The self-collection protocol, which includes the
specimen collection (ie, device), handling (ie, trans-
port buffer and storage conditions), and HPV test,
needs to be validated in limited and basic settings if
notpreviously validated.For example, a temperature
higher than what is recommended or a different
transport medium may affect the test performance.
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Asmore evidenceonself-collection is published, the
Expert Panel will consider whether to make a formal
recommendation.
What Screening Is Recommended for WomenWho
Have Received HPV Vaccination?
Public health providers should consider changes
in cervical cancer screening in the HPV vaccina-
tion era in the absence of the two most carcino-
genic HPV genotypes. As a consequence of the
absenceofHPV16/18,positive screening testswill
be less predictive of CIN3 and cervical cancer
(> CIN3) because the point prevalence of > CIN3
is expected to be reduced by> 50%, whereas the
test positivity will be reduced by < 30%.33,63,64
Moreover, HPV 16– and HPV 18–related cervical
cancers occur at an earlier age than those related
to other HPV genotypes65; therefore, the risk of
cancer is also lowered. Less predictive screening
means a poorer benefit-to-harm ratio. Although
more data are needed, under the assumption that
women were vaccinated before becoming sexu-
ally active, in the enhanced and maximal settings,
women may receive routine screening with HPV
testing at ages 30, 45, and 60 years. However, age
and frequency cannot be fully addressed until there
are more data.
Screening can be changed in several ways to help
restore good benefit-to-harm ratios in bivalent or
quadrivalent HPV-vaccinated populations. First,
screening can be started at an older age than is
currently implemented because the population
risk of cervical cancer will be lower in HPV-
vaccinated (HPV 16 and HPV 18 negative) pop-
ulations and cervical cancer caused by other HPV
genotypes happens at a median age approxi-
mately 5 years older than does cervical cancer
caused by HPV 16 and HPV 18. For example,
many screening programs screen unvaccinated
women under the age of 25 years, despite the lack
of evidence of benefit in this age group,66 and
vaccinatedwomen in this agegroupwouldbeeven
less likely to benefit given their lower cancer risk.
Second, using the principle of equalmanagement
for equal risk,67 longer intervals between screens
and/or follow-up in management could be con-
sidered. This would allow more benign infections
and related abnormalities to clear without detec-
tion and intervention while shifting the focus to
persisting HPV infections that carry a significant
riskofprogression.68,69Finally, new,morespecific
biomarkers couldbeused to triage screen-positive
women to help differentiate between benign hrHPV
infections or related cytologic abnormalities and
clinically important hrHPV infections that have
caused, orwill cause,>CIN3.Althoughmuchmore
data are needed before new approaches can be
implemented into routine screening practices,
the most promising of these biomarkers include
p16/Ki-67 immunocytochemistry,70 E6 oncoprotein
detection,71 andHPVviral genomemethylation.72,73
(See New Screening Technologies for background
and discussion on biomarkers.)
Although it will be at least a decade before we will
consider the predicted impact of the newest HPV
vaccines, in HPV-naı̈ve populations vaccinated
with the nonavalent HPV vaccine, the question
will bewhether to screenat all.Most>CIN3will be
prevented, especially if there is cross-protection
against hrHPV not targeted by nonavalent HPV
vaccine. The few remaining CIN3 diagnoses caused
by borderline hrHPV or low-risk HPV genotypes may
rarely, ifever,becomeinvasivecancer.TheseHPVge-
notypes can still cause significant numbers of minor
cytologic74,75 andhistologic76abnormalities thathave
little clinical importance but would be picked up by
screening. Thus, the harms to the women and costs
would be disproportionately high compared with the
benefits towomen.Speculatively,asinglescreeningof
mid-adult-agedwomen approximately 35 or 40 years
of age may be valuable if it leads to the detection of
early-stage cervical cancer caused by hrHPV types
notcoveredby thenonavalentHPVvaccineorcaused
by borderline hrHPV, and perhaps other female re-
productive tract cancers,77 if the lead-time detection
of the latter provides significant health benefit (eg,
reduced mortality).
New Screening Technologies
Several new technologies are being investigated
for all resource setting levels. They need to be
tested and approved before use in any setting.
These include a number of potentially promising
new biomarkers that might achieve better perfor-
mance as a triage for women with hrHPV-positive
results than cytology and/or HPV genotyping.
The most advanced of these next-generation bio-
markers with respect to validation and readiness
for introduction into routine practice is p16INK4a
immunocytochemistry (p16 ICC). In a number of
studies, p16 ICChasdemonstratedhigh sensitivity
and specificity that is similar to or better than
cytology testing for > CIN2 and > CIN3 among
women with hrHPV-positive results.70,78,79 In ad-
dition, Ki-67, a cell proliferation marker, has been
included with p16 ICC (p16/Ki-67 ICC) as a dual
stain to create a morphology-independent test.70
There is also a manual, lateral flow test for the
detection of E6 protein that was developed for
lower resource settings. The research use–only
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version of the test targeted HPV 16, HPV 18, and
HPV 45 E6 protein, whereas the current commer-
cialized version targets HPV 16 andHPV 18. HPV E6
protein detectionhasbeenshown tobemore specific
than DNA detection for CIN3 and cervical cancer,
even when accounting for restriction to the detection
of the highest risk HPV genotypes.71,80,81 Additional
study is needed to confirm this test’s performance.
There are a considerable number of additional
biomarkers that are being developed. These in-
clude, but are not limited to, viral72,73,82,83 and
host82,84-87 methylation, 3q amplification,88-93 and
viral integration.94,95 All of these new biomarkers
will need further study and validation before use in
any clinical setting, regardless of resource level.
COST AND POLICY IMPLICATIONS
The secondary prevention of cervical cancer is a
cost-effective strategy to reduce the incidence
and mortality of cervical cancer. CEAs discussed
in this guideline support the introduction of HPV
DNA tests in maximal-, enhanced-, and limited-
resource settings and the introduction of VIA
in basic-resource settings. However, there are
specific implementation issues regarding provid-
ing screening and treatment in limited and basic
settings inprimary care, outsideof research studies.
The age group of 30 to 49 years (target age range
recommended in limited- and basic-resources
settings) represents approximately 20% to 25%
of the entire population of women in a given
country. LMICs typically have only basic health
systems, lack resources and facilities, and have
limited or no capacity to manage cancers. These
formidable barriers to starting a screening pro-
gram for this target group can lead to inertia. One
strategy to overcome these barriers is to consider
further restriction of the target age for screening.
Targeting screening to women in their 30s (eg, 30
to 39, 30 to 34, or 35 to 39 years) reduces the
number of women needing screening, thereby
reducing burden on the health care system and
costs, and decreases the number of screen-
detected cancers, which typically peak in women
in their 40s and 50s. Even targeting a single-year
age group, for example, 30 or 31 years, would
enable the development of programs to start and
would help prevent cancer. Whenmore resources
and capacities become available, the program
can be expanded for catch-up screening in older
populations.
Additional strategies to further implementation of
mass screening include buy-in from policymakers,
which affects the provision of resources, including
physical infrastructure, prioritizing cancer pre-
vention, sponsorship of screening, and quality
control. It is important to address this, at a
minimum, by assessing the needs and prefer-
ences, follow-up systems, monitoring, evaluation,
and partnering with institutions, regions, and
countries with treatment facilities. A publication
entitled “Infrastructure Requirements for Human
Papillomavirus Vaccination and Cervical Can-
cer Screening in Sub-Saharan Africa” describes
specific infrastructure elements needed for
screening and cryotherapy programs and can
help program managers plan for obtaining these
elements.10
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementa-
tion across health settings. Barriers to implemen-
tation include the need to increase awareness of
the guideline recommendations among front-line
practitioners and women in general populations
andalso toprovide adequate services in the faceof
limited resources. The guideline Bottom Line Box
was designed to facilitate implementation of rec-
ommendations. This guideline will be distributed
widely, including through many forms of ASCO
communications and the ASCO Web site.
LIMITATIONS OF RESEARCH
There were limitations in the evidence regarding
the best ages for starting and exiting from screen-
ing, screening women with HIV and other types of
immunosuppression, comparative risks and ben-
efits of treatment, and follow-up of women with
precursor lesions. Future research is suggested in
these areas.
FUTURE DIRECTIONS
In addition to addressing research limitations,
future research is needed in other areas (eg,
self-collection, biomarkers, needs and prefer-
ences of women, low-cost technology, and im-
pact of vaccination on screening). Addressing
policy/health system barriers may include the
following:
·Education of medical and public health
communities to change practices and in-
corporate new technologies
·Participation and sponsorship from
policymakers
·Partnerships with institutions, regions, or
countries with treatment facilities
·Coordinated volume purchasing and pro-
curement of HPV testing
16 jgo.ascopubs.org JGO – Journal of Global Oncology
Downloaded from ascopubs.org by Queen Mary and Westfield College on September 6, 2017 from 138.037.213.175
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
·Improvement of health information systems
to have better follow-up and treatment of
women with positive screening results
·Quality control·Monitoring and evaluation
ADDITIONAL RESOURCES
Additional information including a Data Sup-
plement with additional tables, a Methodology
Supplement with information about evidence
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APPENDIX
Table A1 – Panel Members
Member Affiliation Expertise
Jose Jeronimo, MD, Co-Chair, Steering
Committee member
PATH, Seattle, WA Gynecologic Oncology, Cancer
Control
Surendra Shastri, MBBS, MD, DPh, DHA,
Co-Chair, Steering Committee member
Tata Memorial Centre, Mumbai, India Preventive Oncology/Primary Care
Philip Castle, PhD, MPH, Steering
Committee member
Albert Einstein College of Medicine; Global
Coalition against Cervical Cancer,
Arlington, VA
Epidemiology/Biophysics
Lynette Denny, MD, PhD University of Cape Town, Capetown, South
Africa
Gynecologic Oncology
Vandana Gupta V Care, Mumbai, India Patient Representative
Jane J. Kim, PhD Harvard T.H. Chan School of Public
Health, Boston, MA
Health Economics
Eduardo Lazcano, MD, PhD Research Center on Public Health
National Institute of PublicHealth,Mexico
Public Health
Silvana Luciani, MHSc PanAmerican Health Organization,
Washington, DC
Cancer Control
Daniel Murokora, MB, ChB Uganda Women’s Health Initiative,
Kampala, Uganda
Medical Oncology
Twalib Ngoma, MD International Network for Cancer Treatment
and Research, Dar Es Salaam, Tanzania
Radiotherapy and Nuclear Medicine
Youlin Qiao, MD Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing,
China
Cancer Prevention and Control





International Agency for the Research of
Cancer, Lyon, France
Radiotherapy and Oncology; Cancer
Epidemiology and Control
Peter Sasieni, PhD Queen Mary, University of London, Wolfson
Institute, London, United Kingdom
Biostatistics/Epidemiology
Kathleen M. Schmeler, MD The University of Texas, MD Anderson
Cancer Center, Houston, TX
Gynecologic Oncology
Note. American Society of Clinical Oncology staff: Sarah Temin, MSPH.
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Table A2 – Adapted Guidelines and Links
Guideline Link
1 ACS/ASCCP/ASCP; Saslow et al., 201224,25 www.jlgtd.com
2 ASCCP; Massad et al., 201326 www.asccp.org
3 Cancer Care Ontario; Murphy et al., 201127 https://www.cancercare.on.ca/cms/one.aspx?pageId510383
4 Europeanguidelines; vonKarsa et al., 20155 http://www.sciencedirect.com/science/article/pii/S2405852115000129
5 SGO/ASCCP/ACOG/ACS/ASC/CAP/ASCP;
Huh et al., 20156
www.elsevier.com/locate/ygyno
6 WHO Guidelines for Screening and
Treatment of Precancerous Lesions for
Cervical Cancer Prevention, 201328
www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_
precancerous_ lesions/en/index.htm
7 WHO Guidelines for Treatment of Cervical
Intraepithelial Neoplasia
2-3 and Adenocarcinoma In Situ, 201429
www.who.int/reproductivehealth/publications/cancers/treatment_CIN_2-3/en/index.htm
Abbreviations: ACOG, American College of Obstetricians and Gynecologists; ACS, American Cancer Society; ASC, American Society of Cytopathology; ASCCP, American
Society for Colposcopy and Cervical Pathology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; SGO, Society of Gynecologic Oncology.
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